Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019

The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.

Automated summary

This study found similarities in the clinical manifestations and molecular inflammatory responses between COVID-19 patients and HLH patients, but did not support the use of HLH risk-scoring methodology for risk stratification in COVID-19 patients.